Seeking Alpha
 

CTI BioPharma Corp. (CTIC)

- NASDAQ
  • Dec. 10, 2012, 3:24 PM
    Cell Therapeutics (CTIC -5.9%) dips today after its Board of Directors approves amendments to CTI's existing shareholder rights plan to decrease the exercise price of the preferred stock purchase rights from $14.00 to $8.00 and to extend the final expiration date from January 7, 2010, to December 3, 2015. The Rights were initially distributed as a dividend on CTI's common stock.
    | 1 Comment
  • Oct. 15, 2012, 9:10 AM
    Premarket gainers: YONG +15%. CLWR +14%. EDU +14%. AEGR +14%. CEL +9%. MTSL +8%. CTIC +8%. ISIS +7%.
    Losers: DCTH -12%.
    | 1 Comment
  • Oct. 12, 2012, 9:10 AM
    Premarket gainers: NPSP +11%. CTIC +9%. STM +8%.
    Losers: AEZS -24%. AMD -11%. INFY -7%.
    | 1 Comment
  • Oct. 12, 2012, 9:07 AM
    Cell Therapeutics (CTIC) up 8.5% premarket as it announces the closing of its $60M convertible preferred stock offering. The company got about $55.6M after expenses; each share of the Series 17 Preferred is convertible into about 714 shares of common stock at a $1.40/share conversion price. (previously)
    | 2 Comments
  • Oct. 5, 2012, 12:45 PM
    Midday top 10 gainers: PPP +32%. LPHI +19%. EVAC +13%. SNSS +12%. DAC +11%. CUI +10%. XNPT +10%. SHI +10%. NAVR +9%. RPRX +9%.
    Top 10 Losers: PBM -27%. CTIC -23%. ZNGA -18%. MRCY -18%. IFNY.PK -15%. CACH -15%. DTLK -13%. IQNT -13%. FSLR -12%. AEZS -11%.
    | Comment!
  • Oct. 5, 2012, 9:10 AM
    Premarket gainers: PPP +26%. ATHX +9%.
    Losers: CTIC -28%. ZNGA -20%. VRNG -14%. ABR -5%.
    | Comment!
  • Oct. 5, 2012, 7:27 AM
    Cell Therapeutics (CTIC) plummets 21% premarket following the pricing of its offering of 60K shares of convertible preferred stock. Each share is convertible into about 714 shares of common  stock at a price of $1.40, making a total of approximately 42.9M shares. The current outstanding float is 52.25M shares. (PR)
    | 1 Comment
  • Oct. 2, 2012, 12:45 PM
    Midday top 10 gainers: DAEG +18%. PCS +18%. ULTR +16%. KFS +16%. CTIC +16%. UQM +13%. LEAP +13%. DYSL +13%. IMH +13%. SANW +10%.
    Top 10 Losers: PBM -66%. ARQL -54%. MSCI -29%. EXPR -21%. AMCF -18%. CLB -16%. CHC -14%. SKX -11%. CUR -10%. DSTI -10%.
    | Comment!
  • Oct. 2, 2012, 9:10 AM
    Premarket gainers: CTIC +23%. JMBA +11%. ILMN +6%. ROSG +6%.
    Losers: ARQL -61%. EXPR -16%. FNP -14%. LL -7%. GAIN -6%. SFL -6%. GEL -6%.
    | Comment!
  • Oct. 2, 2012, 8:42 AM
    Cell Therapeutics (CTIC) jumps 21% after its Opaxio drug for treating malignant brain cancer receives the FDA's orphan-drug status, which provides the developing company with marketing, fee and tax benefits. The agency assigns the status based on the early results of a Phase II study. (PR)
    | Comment!
  • Sep. 24, 2012, 8:32 AM
    Cell Therapeutics' (CTIC +5.9%) pacritinib drug showed encouraging anti-tumor activity and good tolerability in 34 patients with relapsed or refractory lymphoma in a Phase I trial. Pacritinib has already performed well in Phase II studies for patients with myelofibrosis, and the company intends to carry out Phase III trials for this bone-marrow illness. (PR)
    | Comment!
  • Sep. 19, 2012, 8:37 AM
    Cell Therapeutics (CTIC +0.7%) has regained compliance with Nasdaq's minimum bid price rule. (PR)
    | 2 Comments
  • Sep. 17, 2012, 9:10 AM
    Premarket gainers: IRIS +45%. GNOM +15%. ODP +10%. KTOS +9%. CPRX +9%. TSLA +8%. DVAX +7%. CTIC +6%.
    Losers: THLD -23%.
    | Comment!
  • Sep. 13, 2012, 9:10 AM
    Premarket gainers: EQIX +14%. VICL +13%. APRI +13%. LRN +10%. PLL +7%. CTIC +5%.
    Losers: CCRT -29%. PSTI -17%. FMER -7%. USG -6%. HK -5%.
    | 1 Comment
  • Sep. 11, 2012, 10:48 AM
    Cell Therapeutics (CTIC +32%) rockets higher this morning after announcing the initiation of its commercial launch of Pixuvri in the European Union. Pixuvri is a drug for the treatment of aggressive non-Hodgkin Lymphoma.
    | Comment!
  • Sep. 11, 2012, 9:10 AM
    Premarket gainers: WSB +91%. SNSS +48%. CTIC +15%. NOK +7%. CRTX +7%. RBS +6%. PSTI +5%.
    Losers: NAVB -31%. PPO -12%. PANW -8%. SQNM -7%. PPHM -6%.
    | Comment!
Visit Seeking Alpha's
CTIC vs. ETF Alternatives
Company Description
CTI BioPharma Corp., is a biopharmaceutical company focused on the acquisition, development and commercialization of less toxic and more effective ways to treat cancer.
Sector: Healthcare
Industry: Biotechnology
Country: United States